Archives: Fichas

EAU Guidelines on Urethral Carcinoma II

Explore this #EAUUrologyCheatSheet, spotlighting #PrimaryUrethralCarcinoma. It’s a complete guide for managing this condition. Check it out now! #EAUguidelines

Sexually Transmitted Infections II: genital lesions

Our latest #UrologyCheatSheet is here, bringing together the key genital lesions caused by sexually transmitted infections. The most common agents are human papillomavirus, herpes simplex virus, and Treponema pallidum. Dive into essential information and guidance for diagnosis and treatment.

EAU Guidelines on Urolithiasis II

Urolithiasis treatment is based on many parameters and is individualised for each patient, whether it is renal colic or an obstruction. Review the disease management #EAUGuidelines in this #EAUUrologyCheatSheets on #Urolithiasis.

EAU Guidelines on Prostate Cancer III

This #EAUUrologyCheatSheets is a review of the #EAUGuidelines for the treatment of #ProstateCancer. It represents a collaborative effort between the EAU and numerous partners to provide a concise yet comprehensive overview of treatment pathways.

EAU Guidelines on Non-muscle-invasive Bladder Cancer

Dive into our new #EAUUrologyCheatSheets focusing on non-muscle invasive bladder cancer #NMIBC. Learn more about risk stratification and disease management – essential resources for improving patient care. #BladderCancer

EAU Guidelines on Urological Infections II

Recurrent UTIs (rUTIs) include both cystitis and pyelonephritis, but repeated pyelonephritis should prompt the consideration of complicated aetiology. Review the #EAUGuidelines on #UTI (recurrent urinary tract infections and uncomplicated pyelonephritis ) with this #EAUUrologyCheatSheets!

EAU Guidelines on Penile Cancer

Our newest #EAUUrologyCheatSheets is a collaborative effort with @ASCO to create comprehensive guidelines on #PenileCancer. Review the updated #EAUGuidelines on #PenileCarcinoma with this one page cheat sheet!

BCG treatment in high-risk non-muscle invasive bladder tumours: possible situations after its use By Jorge Huguet

BCG is an effective treatment for high-risk non-muscle invasive bladder tumors, with response rates of around 70%. However, progression during BCG treatment can occur in 9.5%-21% of cases, resulting in a worse patient prognosis. If there is no response to BCG or BCG failure occurs, the European Association of Urology (EAU) guidelines have defined different …

BCG treatment in high-risk non-muscle invasive bladder tumours: possible situations after its use By Jorge Huguet Read More »

Subscribe to our newsletter